Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M. Persano M, et al. Among authors: morishita a. Oncology. 2024 Oct 11:1-13. doi: 10.1159/000541018. Online ahead of print. Oncology. 2024. PMID: 39396495
Primary hepatic neuroendocrine tumor: A case report.
Morishita A, Yoneyama H, Nomura T, Sakamoto T, Fujita K, Tani J, Miyoshi H, Haba R, Masaki T. Morishita A, et al. Mol Clin Oncol. 2016 Jun;4(6):954-956. doi: 10.3892/mco.2016.822. Epub 2016 Mar 17. Mol Clin Oncol. 2016. PMID: 27284429 Free PMC article.
MicroRNA profiles in various hepatocellular carcinoma cell lines.
Morishita A, Iwama H, Fujihara S, Sakamoto T, Fujita K, Tani J, Miyoshi H, Yoneyama H, Himoto T, Masaki T. Morishita A, et al. Oncol Lett. 2016 Sep;12(3):1687-1692. doi: 10.3892/ol.2016.4853. Epub 2016 Jul 13. Oncol Lett. 2016. PMID: 27588118 Free PMC article.
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Tsutsui A, Senoh T, Nagano T, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kokudo Y, Minami Y, Ueshima K, Sakurai T, Nishida N, Kudo M. Ogawa C, et al. Among authors: morishita a. Oncology. 2017;93 Suppl 1:113-119. doi: 10.1159/000481241. Epub 2017 Dec 20. Oncology. 2017. PMID: 29258090 Clinical Trial.
Serum microRNA-125a-5p as a potential biomarker of HCV-associated hepatocellular carcinoma.
Oura K, Fujita K, Morishita A, Iwama H, Nakahara M, Tadokoro T, Sakamoto T, Nomura T, Yoneyama H, Mimura S, Tani J, Kobara H, Okano K, Suzuki Y, Masaki T. Oura K, et al. Among authors: morishita a. Oncol Lett. 2019 Jul;18(1):882-890. doi: 10.3892/ol.2019.10385. Epub 2019 May 21. Oncol Lett. 2019. PMID: 31289566 Free PMC article.
Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion.
Nomura T, Tani J, Deguchi A, Nakahara M, Oura K, Tadokoro T, Fujita K, Mimura S, Sakamoto T, Morishita A, Yoneyama H, Kobara H, Sanomura T, Nishiyama Y, Okano K, Suzuki Y, Takahashi S, Shibata T, Tsutsui K, Himoto T, Masaki T. Nomura T, et al. Among authors: morishita a. Mol Clin Oncol. 2019 Nov;11(5):447-454. doi: 10.3892/mco.2019.1920. Epub 2019 Sep 9. Mol Clin Oncol. 2019. PMID: 31602300 Free PMC article.
Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T. Toyoda H, et al. Among authors: morishita a. J Gastroenterol Hepatol. 2020 May;35(5):855-861. doi: 10.1111/jgh.14874. Epub 2019 Nov 19. J Gastroenterol Hepatol. 2020. PMID: 31609495 Clinical Trial.
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T. Toyoda H, et al. Among authors: morishita a. J Gastroenterol Hepatol. 2020 Aug;35(8):1420-1425. doi: 10.1111/jgh.14982. Epub 2020 Jan 31. J Gastroenterol Hepatol. 2020. PMID: 31950525
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group. Nozaki A, et al. Among authors: morishita a. Hepatol Int. 2020 Mar;14(2):225-238. doi: 10.1007/s12072-020-10019-z. Epub 2020 Mar 3. Hepatol Int. 2020. PMID: 32128704
Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study.
Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Tani J, et al. Among authors: morishita a. Oncol Lett. 2020 Mar;19(3):2205-2212. doi: 10.3892/ol.2020.11341. Epub 2020 Jan 23. Oncol Lett. 2020. PMID: 32194718 Free PMC article.
423 results